„Enthusiast meets the Experienced“: Pneumo meets … Rheumatologie

[1]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.

[2]  F. Martinez,et al.  Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2022, American journal of respiratory and critical care medicine.

[3]  M. Kreuter,et al.  Entwicklung und Fortschritt bei interstitiellen Lungenerkrankungen , 2022, Wiener klinisches Magazin.

[4]  L. Mouthon,et al.  Treatment of relapsing polychondritis: a systematic review. , 2021, Clinical and experimental rheumatology.

[5]  H. Schäfers,et al.  Chronic Thromboembolic Pulmonary Hypertension in Patients with Antiphospholipid Syndrome: Risk Factors and Management , 2021, The Journal of Heart and Lung Transplantation.

[6]  K. Oniszh,et al.  Dominating Cause of Pulmonary Hypertension May Change Over Time—Diagnostic and Therapeutic Considerations in a Patient with Pulmonary Hypertension Due to Rheumatoid Arthritis with Lung Involvement , 2021, Diagnostics.

[7]  A. Krause,et al.  Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien) , 2021, Zeitschrift für Rheumatologie.

[8]  M. Kreuter,et al.  Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study , 2021, Thorax.

[9]  P. Dieudé,et al.  Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials , 2021, Rheumatology and Therapy.

[10]  C. Heussel,et al.  The Diagnosis and Treatment of Pulmonary Fibrosis. , 2021, Deutsches Arzteblatt international.

[11]  J. Goldin,et al.  Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease , 2021, Arthritis & rheumatology.

[12]  M. Gatto,et al.  Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review , 2021, Therapeutic advances in musculoskeletal disease.

[13]  C. Denton,et al.  Rituximab for the treatment of systemic sclerosis-interstitial lung disease. , 2020, Rheumatology.

[14]  S. Castañeda,et al.  Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. , 2020, Rheumatology.

[15]  M. Nikpour,et al.  Cancer and scleroderma: recent insights , 2020, Current opinion in rheumatology.

[16]  L. Czirják,et al.  Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database , 2020, Annals of the Rheumatic Diseases.

[17]  A. Krause,et al.  Lungenmanifestationen rheumatischer Erkrankungen schon früh mitbedenken , 2020, Pneumo News.

[18]  J. Park,et al.  Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[19]  M. Kreuter,et al.  The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease , 2020, Respiratory Research.

[20]  J. Alves,et al.  Connective tissue disease-associated interstitial lung disease. , 2020, Pulmonology.

[21]  B. Griffiths,et al.  The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. , 2020, The Lancet. Rheumatology.

[22]  K. Liao,et al.  Rheumatoid arthritis increases the risk of pleural empyema , 2020, Open medicine.

[23]  Ø. Molberg,et al.  Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. , 2019, American journal of respiratory and critical care medicine.

[24]  M. Leandro,et al.  The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. , 2019, Rheumatology.

[25]  T. Maher,et al.  Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease , 2019, Expert review of clinical immunology.

[26]  M. Revel,et al.  Tracheobronchial involvement of relapsing polychondritis. , 2019, Autoimmunity reviews.

[27]  M. Dougados,et al.  2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.

[28]  M. Kreuter,et al.  Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management , 2019, Current medical research and opinion.

[29]  Yao Huang,et al.  Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? , 2019, Drug design, development and therapy.

[30]  T. Welte,et al.  Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. , 2019, Deutsches Arzteblatt international.

[31]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[32]  D. Walsh,et al.  Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts , 2019, BMJ Open.

[33]  V. Cottin,et al.  Lung Diseases in Inflammatory Myopathies , 2019, Seminars in Respiratory and Critical Care Medicine.

[34]  J. Coghlan,et al.  Pulmonary Hypertension Associated with Connective Tissue Disease , 2019, Seminars in Respiratory and Critical Care Medicine.

[35]  P. Merkel,et al.  Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. , 2019, Rheumatology.

[36]  D. Khanna,et al.  Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features , 2019, RMD Open.

[37]  D. Lynch,et al.  Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities , 2019, Arthritis & rheumatology.

[38]  V. Cottin,et al.  Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. , 2019, Autoimmunity reviews.

[39]  L. Flores-Suárez,et al.  Frequency, treatment, evolution, and factors associated with the presence of tracheobronchial stenoses in granulomatosis with polyangiitis. Retrospective analysis of a case series from a single respiratory referral center. , 2019, Seminars in arthritis and rheumatism.

[40]  R. Takei,et al.  Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease , 2019, Modern rheumatology.

[41]  S. Birring,et al.  Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[42]  Z. Jing,et al.  Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. , 2018, Autoimmunity reviews.

[43]  Christie M. Bartels,et al.  Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis. , 2018, Seminars in arthritis and rheumatism.

[44]  A. Tincani,et al.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. , 2018, Blood.

[45]  J. Roscamp,et al.  Relapsing polychondritis: a clinical review for rheumatologists. , 2018, Rheumatology.

[46]  Y. Yamaguchi,et al.  Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients , 2018, Rheumatology.

[47]  E. V. van Daalen,et al.  Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy , 2018, Current opinion in rheumatology.

[48]  M. Kreuter,et al.  Palliative care in interstitial lung disease: living well. , 2017, The Lancet. Respiratory medicine.

[49]  C. Koegelenberg,et al.  Recurrent Pulmonary Aneurysms: Hughes-Stovin Syndrome on the Spectrum of Behçet Disease. , 2017, Chest.

[50]  Z. Xiong,et al.  [Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography]. , 2017, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[51]  O. Hilberg,et al.  A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality , 2017, Annals of the rheumatic diseases.

[52]  M. Mejía,et al.  Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis , 2017, Clinical Rheumatology.

[53]  J. Carey,et al.  Methotrexate and lung disease in rheumatoid arthritis. , 2017, Panminerva medica.

[54]  J. Ryu.  Faculty of 1000 evaluation for An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. , 2016 .

[55]  T. Panchabhai,et al.  Lymphocytic Interstitial Pneumonia. , 2016, Clinics in chest medicine.

[56]  H. Lorenz,et al.  Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response , 2016, Journal of Rheumatology.

[57]  X. Mariette,et al.  Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. , 2015, Rheumatology.

[58]  D. Lynch,et al.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.

[59]  J. Gris,et al.  Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients , 2009, Annals of the rheumatic diseases.

[60]  J. Ryu,et al.  Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia , 2014, Respiratory Research.

[61]  T. Colby,et al.  Usual Interstitial Pneumonia Preceding Collagen Vascular Disease: A Retrospective Case Control Study of Patients Initially Diagnosed with Idiopathic Pulmonary Fibrosis , 2014, PloS one.

[62]  J. Carey,et al.  Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials , 2014, Arthritis & rheumatology.

[63]  S. Bombardieri,et al.  The diagnosis and classification of mixed connective tissue disease. , 2014, Journal of autoimmunity.

[64]  H. Heinzl,et al.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study , 2013, Annals of the rheumatic diseases.

[65]  A. Fischer,et al.  Interstitial lung disease in connective tissue disorders , 2012, The Lancet.

[66]  J. Piette,et al.  Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. , 2012, Arthritis and rheumatism.

[67]  J. Huggins,et al.  Chylothorax and Cholesterol Pleural Effusion , 2010, Seminars in respiratory and critical care medicine.

[68]  A. Wells.  The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease , 2010, European Respiratory Review.

[69]  H. Collard,et al.  Pulmonary rehabilitation for interstitial lung disease. , 2010, Chest.

[70]  K. Lewis.  Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2008 .

[71]  G. Alarcón,et al.  Pulmonary manifestations of rheumatoid arthritis. , 2007, Seminars in respiratory and critical care medicine.

[72]  Charles Thompson,et al.  The need for a holistic approach , 2007 .

[73]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[74]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[75]  Y. Tsunezuka,et al.  Tracheobronchial Involvement in Relapsing Polychondritis , 2000, Respiration.

[76]  T. Medsger,et al.  Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.

[77]  M. Hargreaves,et al.  Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. , 1992, Thorax.